Regencell Financial Statements From 2010 to 2025

RGC Stock  USD 18.50  5.88  46.59%   
Regencell Bioscience financial statements provide useful quarterly and yearly information to potential Regencell Bioscience Holdings investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Regencell Bioscience financial statements helps investors assess Regencell Bioscience's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Regencell Bioscience's valuation are summarized below:
Market Capitalization
164.2 M
Earnings Share
(0.33)
We have found one hundred twenty available trending fundamental ratios for Regencell Bioscience, which can be analyzed and compared to other ratios and to its competitors. Investors should ensure to check out all of Regencell Bioscience's recent performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 1.6 B. The current year's Enterprise Value is expected to grow to about 3.3 B

Regencell Bioscience Total Revenue

0.0

Check Regencell Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regencell Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 637.5 K, Interest Expense of 19.8 K or Selling General Administrative of 3.1 M, as well as many indicators such as Price To Sales Ratio of 0.36, Dividend Yield of 0.0 or Days Sales Outstanding of 12.61. Regencell financial statements analysis is a perfect complement when working with Regencell Bioscience Valuation or Volatility modules.
  
Check out the analysis of Regencell Bioscience Correlation against competitors.

Regencell Bioscience Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets7.2 M7.6 M1.3 B
Slightly volatile
Short and Long Term Debt Total73.3 K77.2 K986.2 M
Slightly volatile
Other Current Liabilities114.4 K120.4 K55.9 M
Slightly volatile
Total Current Liabilities165.5 K174.2 K231.9 M
Slightly volatile
Property Plant And Equipment Net193.7 K203.9 K756.6 M
Slightly volatile
Current Deferred Revenue224.8 M214.1 M169 M
Slightly volatile
Accounts Payable200 M267 M208.6 M
Slightly volatile
Cash2.5 M2.7 M111.1 M
Slightly volatile
Cash And Short Term Investments6.8 M7.2 M113.9 M
Slightly volatile
Good Will266.7 M397.7 M315.9 M
Slightly volatile
Common Stock Shares Outstanding11.1 M11.7 M83.7 M
Slightly volatile
Liabilities And Stockholders Equity7.2 M7.6 M1.3 B
Slightly volatile
Non Current Liabilities Total28.3 K29.8 K1.2 B
Slightly volatile
Other Current Assets130.6 K137.5 K29.1 M
Slightly volatile
Total Liabilities187.7 K197.6 K1.5 B
Slightly volatile
Total Current Assets6.9 M7.3 M203.5 M
Slightly volatile
Short Term Debt51.1 K53.8 K14.7 M
Slightly volatile
Intangible Assets38.4 M50.1 M41.6 M
Slightly volatile
Net Receivables130.6 K137.5 K65.5 M
Slightly volatile
Common Stock11111750.1 K
Slightly volatile
Common Stock Total Equity85.590.050 K
Slightly volatile
Property Plant And Equipment Gross864.1 K909.6 K703.1 M
Slightly volatile
Short and Long Term Debt3.2 M4.2 M2.8 M
Slightly volatile
Capital Stock126150110
Slightly volatile
Property Plant Equipment1.8 M1.7 M561.7 K
Slightly volatile
Deferred Long Term Liabilities137.9 K155.1 K169.1 K
Slightly volatile

Regencell Bioscience Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization637.5 K671 K102.8 M
Slightly volatile
Selling General Administrative3.1 M3.3 M91.7 M
Slightly volatile
Other Operating ExpensesM4.3 M1.3 B
Slightly volatile
Cost Of Revenue814.6 K857.4 K191.5 M
Pretty Stable
Total Operating Expenses3.4 M3.6 M678.1 M
Slightly volatile
Selling And Marketing Expenses317.2 K302.1 K82.4 K
Slightly volatile
Research Development1.1 M1.2 M650.2 K
Slightly volatile

Regencell Bioscience Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow1.3 M1.4 M96.2 M
Slightly volatile
Depreciation637.5 K671 K102.8 M
Slightly volatile
Dividends Paid191.8 M125 M151.9 M
Very volatile
End Period Cash Flow2.5 M2.7 M111.1 M
Slightly volatile
Change To Netincome2.2 M2.3 M2.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.360.470.5167
Slightly volatile
Days Sales Outstanding12.6119.1118.644
Slightly volatile
Capex To Depreciation1.280.98272.2578
Very volatile
EV To Sales0.781.081.1529
Slightly volatile
Payables Turnover0.450.481.2091
Pretty Stable
Sales General And Administrative To Revenue0.04290.02460.044
Pretty Stable
Capex To Revenue0.03990.07120.0659
Slightly volatile
Cash Per Share1.391.46351.0052
Pretty Stable
Days Payables Outstanding556792578
Slightly volatile
Income Quality2.793.652.2447
Slightly volatile
Intangibles To Total Assets0.0880.120.1326
Pretty Stable
Current Ratio0.780.82536.1037
Slightly volatile
Receivables Turnover27.6319.7720.0037
Slightly volatile
Capex Per Share1.681.60170.7894
Pretty Stable
Revenue Per Share22.123.2720.1515
Slightly volatile
Interest Debt Per Share14.3815.13418.7297
Slightly volatile
Debt To Assets1.40.83222.1381
Pretty Stable
Graham Number2.712.853.1856
Slightly volatile
Days Of Payables Outstanding556792578
Slightly volatile
Pretax Profit Margin0.09060.07780.0733
Very volatile
Ebt Per Ebit0.620.78730.7943
Slightly volatile
Operating Profit Margin0.120.09880.0999
Slightly volatile
Long Term Debt To Capitalization0.741.421.4507
Very volatile
Ebit Per Revenue0.120.09880.0999
Slightly volatile
Quick Ratio0.750.78456.0903
Slightly volatile
Net Income Per E B T0.540.5250.7271
Slightly volatile
Cash Ratio0.390.40762.0784
Slightly volatile
Operating Cash Flow Sales Ratio0.150.12960.1333
Very volatile
Days Of Sales Outstanding12.6119.1118.644
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.610.38910.7387
Slightly volatile
Fixed Asset Turnover1.261.881.9793
Very volatile
Debt Ratio1.40.83222.1381
Pretty Stable
Price Sales Ratio0.360.470.5167
Slightly volatile
Asset Turnover0.881.01.1114
Slightly volatile
Net Profit Margin0.05460.04080.0414
Pretty Stable
Gross Profit Margin0.981.110.9289
Pretty Stable

Regencell Bioscience Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.6 B1.5 B416.6 M
Slightly volatile
Enterprise Value3.3 B3.2 B677.8 M
Slightly volatile

Regencell Fundamental Market Drivers

Cash And Short Term InvestmentsM

Regencell Upcoming Events

26th of January 2024
Upcoming Quarterly Report
View
30th of September 2023
Next Fiscal Quarter End
View

About Regencell Bioscience Financial Statements

Regencell Bioscience stakeholders use historical fundamental indicators, such as Regencell Bioscience's revenue or net income, to determine how well the company is positioned to perform in the future. Although Regencell Bioscience investors may analyze each financial statement separately, they are all interrelated. For example, changes in Regencell Bioscience's assets and liabilities are reflected in the revenues and expenses on Regencell Bioscience's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Regencell Bioscience Holdings. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue214.1 M224.8 M
Cost Of Revenue857.4 K814.6 K
Sales General And Administrative To Revenue 0.02  0.04 
Capex To Revenue 0.07  0.04 
Revenue Per Share 23.27  22.10 
Ebit Per Revenue 0.10  0.12 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock:
Check out the analysis of Regencell Bioscience Correlation against competitors.
You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.33)
Return On Assets
(0.28)
Return On Equity
(0.43)
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.